Search Results for "Xalacom And Xalatan"
Original Source: A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH.
Matching Channels
The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...
Matching News
Pharma Showdown: Johnson & Johnson Vs. Pfizer
ByCatalyst Investments:Johnson & Johnson (JNJ) and Pfizer (PFE) are leaders in the pharmaceutical/healthcare field, and both are sought after growth stocks with a bonus of solid dividend yields, b...
Pfizer Fights Patent Losses With Divestments
By Peter Pham:Pfizer Inc (PFE), the world's biggest pharmaceutical company, posted an enormous increase in quarterly profits from $1.4 billion in Q4-2011 to $6.3 billion in Q4-2012 because of the $11....
Ocular Therapeutix Discloses Promising Results for Extended Release Treatment of Glaucoma
BEDFORD, Mass., July 23, 2012 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatmen...
Alimera Sciences Names European Management Team
ATLANTA, Nov. 14, 2012 /PRNewswire/ -- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescri...
Pfizer Reports Second-Quarter 2012 Results
Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts)...
Fitch Affirms Allergan's IDR at 'A+'; Rates New Debt
Fitch Ratings has affirmed Allergan Inc.'s (Allergan) Issuer Default Rating (IDR) at 'A+'. A complete list of ratings affirmed is provided at the end of this release....
Bausch + Lomb Initiates Phase 3 Program for Glaucoma Drug Candidate Licensed From Nicox
SOPHIA ANTIPOLIS, FRANCE and MADISON, NJ -- (Marketwire) -- 01/29/13 -- Bausch + Lomb Initiates Phase 3 Program for Glaucoma Drug Candidate Licensed from Nicox Bausch + Lomb, the global eye healt...
Matching PubMed Articles
Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.
PURPOSE: To confirm the possible mechanism by which topical prostaglandin antiglaucoma drugs cause a deep superior sulcus. METHODS: Among patients who used bimatoprost (Lumigan), latanoprost (Xalatan)...
Assessment of aqueous humor dynamics in the mouse by a novel method of constant flow infusion.
PURPOSE: To characterize a technique that concurrently assesses all aqueous humor hydrodynamic parameters in mouse eyes. METHODS: Mouse outflow facility (C) was determined by multiple flow-rate infusi...
A review of the use of latanoprost for glaucoma since its launch.
Introduction: Prostaglandins are increasingly used as first choice treatment for glaucoma because they are highly effective, lack relevant systemic side effects and require just once-daily administrat...
